ArticlePharmaceuticals (Basel, Switzerland)2023

Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database.

Yi Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.